A Fifth Circuit ruling that keeps mifepristone available, but curtails access to it, is the newest front in a battle over the FDA’s power to approve medications.
Read the story here.
Everyone Was Wrong About Antipsychotics
10:28
Covid’s Summer Wave Is Rising—Again
07:56
This Prosthetic Limb Actually Attaches to the Wearer’s Nerves
08:47